Allostery Investments LP

CIK

1978599

Location

Stamford, CT

Portfolio Value

Micro $7,462,643

Diversification

Diversified

Filing Date

Global Rank

#8,074 / 8,137 ▼ 278 · as of Jun 2025

Top Industry

Biotechnology 77.2%

Period ended 1 year ago

Filed Aug 14, 2025 · 1y

3 quarters · since Dec 2024

Regulatory profile

From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.

Holder type

Unknown

Schedule 13D/13G stakes

Stakes of 5% or more disclosed on Schedule 13D or 13G, each on the filer's latest filing for the security. These are event-dated stakes, not the quarter-end 13F portfolio below.

No stake currently held at or above 5%.

A 13D or 13G stays in force until its filer amends it and no amendment is due without a material change, so a stake with no filing in 24 months reads unconfirmed, never sold. An amendment reporting under 5% ends the filer's duty to amend, not necessarily the holding. Shares are restated onto today's split basis. Show 2 exited, below-5% or retired stakes

Portfolio style

Measured from the filed 13F common-share book for Jun 30, 2025, never from the firm's own description.

Style

Unknown

$7,462,643 of valued equity, under the $10,000,000 needed to band a style

Turnover

Turnover unknown

It needs four straight quarters of measured turnover

Horizon

Short horizon

Value-weighted holding period 2.4 quarters (under 4)

Closest benchmark: the Russell 2000 as of 2025-06-30, active share 99.2%; sector active share 78.8% against the combined 13F book's sector weights.

Over time 3 measured quarters

How the bands are measured

Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.

Clone Performance

Build a hypothetical price-return history from this filer's public 13F holdings.

View clone backtest

Portfolio Concentration

19 tracked positions · as of Jun 30, 2025 · Δ vs Mar 31, 2025

Top Position

17.2%

+7.1 pts

Top 5

60.2%

+19.5 pts

Top 10

87.0%

+20.9 pts

HHI

979

Diversified+438

Portfolio Trend

3 quarters · across all stocks

Sector Breakdown

As of Jun 30, 2025

Sector	% Portfolio	Value	Positions
Healthcare	77.6%	$5,788,643	16
Unclassified	22.4%	$1,674,000	3

Last Quarter's Activity

Export CSV

Jun 30, 2025 vs Mar 31, 2025

Added To

Positions the filer increased

1 positions

Ticker	Company	Δ Shares	Shares	Value	Open
—		+4,500	22,500	$1,200,600
No positions match the current search.

Trimmed

Positions the filer reduced

13 positions

Ticker	Company	Δ Shares	Shares	Value
ABVX	Abivax S.A.	−932,304	167,350	$1,280,227
—		−418,302	40,000	$452,200
EOLS	Evolus, Inc.	−352,754	60,000	$552,600
CNTA	Centessa Pharmaceuticals plc	−330,024	52,500	$689,850
AMLX	Amylyx Pharmaceuticals, Inc.	−145,980	120,119	$769,962
—		−115,657	9,000	$473,400
—		−104,000	6,000	$260,580
AVTX	Avalo Therapeutics, Inc.	−98,141	9,000	$44,910
PMN	ProMIS Neurosciences Inc.	−77,983	155,720	$74,745
BBIO	BridgeBio Pharma, Inc.	−76,000	4,000	$172,720
CYTK	Cytokinetics Inc	−65,000	5,000	$165,200
—		−43,000	1,000	$65,850
LEGN	Legend Biotech Corp	−750	4,000	$141,960
No positions match the current search.

New Positions

Positions the filer opened this quarter

5 positions

Ticker	Company	Shares	Value
RZLT	Rezolute, Inc.	119,294	$532,051
FULC	Fulcrum Therapeutics, Inc.	40,353	$277,628
TNGX	Tango Therapeutics, Inc.	40,000	$204,800
NKTR	Nektar Therapeutics	4,000	$103,360
—		9,356	$0
No positions match the current search.

Sold Out

Positions the filer fully exited

25 positions

Ticker	Company	Shares	Value
ALKS	Alkermes plc.	115,000	$3,797,300
AVTE	Jade Biosciences, Inc.	1,421,568	$3,568,136
ZURA	Zura Bio Ltd	2,329,384	$3,004,905
—		52,500	$2,316,825
BEAM	Beam Therapeutics Inc.	92,754	$1,811,485
—		20,000	$1,429,000
PCVX	Vaxcyte, Inc.	32,000	$1,208,320
IONS	Ionis Pharmaceuticals Inc	35,000	$1,055,950
XENE	Xenon Pharmaceuticals Inc.	30,000	$1,006,500
INSM	INSMED Inc	10,000	$762,900
TARS	Tarsus Pharmaceuticals, Inc.	13,600	$698,632
GOSS	Gossamer Bio, Inc.	613,028	$674,330
PLRX	Pliant Therapeutics, Inc.	441,686	$596,276
CNTX	Context Therapeutics Inc.	950,166	$581,501
HLSQ	Tessera Defense & Homeland Security Inc.	940,629	$522,708
RLYB	Rallybio Corp	752,235	$492,713
ELDN	Eledon Pharmaceuticals, Inc.	100,000	$339,000
CLYM	Climb Bio, Inc.	244,988	$298,885
ORKA	Oruka Therapeutics, Inc.	20,000	$205,200
MDGL	Madrigal Pharmaceuticals, Inc.	600	$198,738
—		25,000	$181,750
VIR	Vir Biotechnology, Inc.	22,202	$143,868
WVE	Wave Life Sciences, Inc.	17,500	$141,400
ARQT	Arcutis Biotherapeutics, Inc.	7,500	$117,300
EWTX	Edgewise Therapeutics, Inc.	3,000	$66,000
No positions match the current search.

Portfolio Positions

Compact Export CSV View 13F filing

19 tracked positions · $7,462,643 total · filing declares 20 positions · $7,850,255 · as of Jun 30, 2025

All sectors Healthcare

Ticker	Company	Type	Shares	Δ Shares	Value (USD)	% Δ Value	Held (qtrs)	Est. cost/share	% of Portfolio
ABVX	Abivax S.A. Healthcare	Reduced	167,350	-932,304	$1,280,227	−81.4%	3	before history	17.16%
		Added	22,500	+4,500	$1,200,600	+64.8%	2	unpriced	16.09%
AMLX	Amylyx Pharmaceuticals, Inc. Healthcare	Reduced	120,119	-145,980	$769,962	−18.3%	2	$3.56	10.32%
CNTA	Centessa Pharmaceuticals plc Healthcare	Reduced	52,500	-330,024	$689,850	−87.5%	3	before history	9.24%
EOLS	Evolus, Inc. Healthcare	Reduced	60,000	-352,754	$552,600	−88.9%	3	before history	7.40%
RZLT	Rezolute, Inc. Healthcare	NEW	119,294	NEW	$532,051	NEW	1	$3.71	7.13%
		Reduced	9,000	-115,657	$473,400	−91.0%	3	before history	6.34%
		Reduced	40,000	-418,302	$452,200	−91.4%	3	before history	6.06%
FULC	Fulcrum Therapeutics, Inc. Healthcare	NEW	40,353	NEW	$277,628	NEW	1	$5.35	3.72%
		Reduced	6,000	-104,000	$260,580	−93.7%	3	before history	3.49%
TNGX	Tango Therapeutics, Inc. Healthcare	NEW	40,000	NEW	$204,800	NEW	1	$2.47	2.74%
BBIO	BridgeBio Pharma, Inc. Healthcare	Reduced	4,000	-76,000	$172,720	−93.8%	2	$33.72	2.31%
CYTK	Cytokinetics Inc Healthcare	Reduced	5,000	-65,000	$165,200	−94.1%	3	before history	2.21%
LEGN	Legend Biotech Corp Healthcare	Reduced	4,000	-750	$141,960	−11.9%	2	$35.86	1.90%
NKTR	Nektar Therapeutics Healthcare	NEW	4,000	NEW	$103,360	NEW	1	unpriced	1.39%
PMN	ProMIS Neurosciences Inc. Healthcare	Reduced	155,720	-77,983	$74,745	−54.3%	3	before history	1.00%
		Reduced	1,000	-43,000	$65,850	−97.7%	3	before history	0.88%
AVTX	Avalo Therapeutics, Inc. Healthcare	Reduced	9,000	-98,141	$44,910	−94.8%	3	before history	0.60%
		NEW	9,356	NEW	$0	NEW	1	unpriced	0.00%

Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.